Edition:
India

Intellipharmaceutics International Inc (IPCI.OQ)

IPCI.OQ on NASDAQ Stock Exchange Capital Market

0.88USD
20 Nov 2017
Change (% chg)

$-0.04 (-4.35%)
Prev Close
$0.92
Open
$0.90
Day's High
$0.91
Day's Low
$0.88
Volume
61,238
Avg. Vol
57,073
52-wk High
$3.34
52-wk Low
$0.82

Select another date:

Wed, Oct 11 2017

BRIEF-Intellipharmaceutics announces US$4 mln registered direct offering

* Intellipharmaceutics announces US$4 million registered direct offering

BRIEF-Intellipharmaceutics- Q3 loss per share $0.08

* Intellipharmaceutics International Inc - ‍ expects revenue from generic Seroquel XR to increase going forward​ Source text for Eikon: Further company coverage:

FDA declines to approve Intellipharma's opioid painkiller

Intellipharmaceutics International Inc, said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its opioid painkiller in its current form, asking for more proof of the drug's ability to prevent abuse.

UPDATE 1-FDA declines to approve Intellipharma's opioid painkiller

Sept 25Intellipharmaceutics International Inc said on Monday the U.S. Food and Drug Administration (FDA) declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities.

BRIEF-Intellipharmaceutics receives complete response letter from FDA for Rexista NDA

* Intellipharmaceutics receives complete response letter from the FDA for rexista™ NDA

FDA declines to approve Intellipharma's opioid painkiller

Sept 25Intellipharmaceutics International Inc said on Monday that the U.S. Food and Drug Administration declined to approve its long-acting opioid painkiller in its current form, backing its independent advisory panel that had raised concerns over the drug's abuse-deterrence capabilities.

BRIEF-Intellipharmaceutics provides operational update on its Rexista(TM) program

* Currently anticipate Rexista program​ study will take nine months from commencement to complete

Fitch Affirms Brinker's IDR at 'BB+' IDR; Outlook Revised to Negative

(The following statement was released by the rating agency) CHICAGO, August 17 (Fitch) Fitch Ratings has affirmed Brinker, International, Inc.'s (Brinker) Issuer Default Rating (IDR) at 'BB+' and revised its Rating Outlook to Negative from Stable. Brinker's ratings reflect its moderately high leverage, meaningful free cash flow, and the position of Chili's Grill & Bar (Chili's) as one of the largest U.S. casual dining chains in the U.S. The company's ratings consider secular challenges in the ca

BRIEF-Intellipharmaceutics announces resignation of CFO

* Intellipharmaceutics announces resignation of chief financial officer

BRIEF-Intellipharmaceutics says purported class action complaint was filed by Shawn Shanawaz

* Intellipharmaceutics International - on July 28, purported class action complaint was filed in U.S. Court By Shawn Shanawaz

Select another date: